Lancet: The incidence of atrial fibrillation is getting higher and higher, and early screening of the elderly has obvious benefits!

Atrial fibrillation is abbreviated as atrial fibrillation, which is the most common type of persistent arrhythmia in clinical practice
.

In atrial fibrillation, the atrium loses its normal and effective contraction function and is in a state of rapid and disordered fibrillation, the frequency can be as fast as 300-600 beats/minute, and the ventricle beats quickly and irregularly, which can reach 100-200 beats/minute

In arrhythmia with atrial fibrillation, the atrium loses its normal and effective contraction function and is in a state of rapid and disordered fibrillation, the frequency can be as fast as 300-600 beats/minute, and the ventricle beats quickly and irregularly, which can reach 100-200 beats/minute

Approximately one-tenth of people aged 80 years and older suffer from atrial fibrillation.

Screening

STROKESTOP is a multicenter, parallel group, unmasked randomized controlled trial conducted in Harland and Stockholm, Sweden
.

All 75-76 year-olds living in these two regions were randomly assigned (1:1) and invited to participate in atrial fibrillation screening or control group

From March 1, 2012 to May 28, 2014, 28768 people underwent eligibility assessment and were randomly assigned to be invited to participate in the screening (n=14387) or control group (n=14381)
.

Among those invited to participate in the screening, 7,165 (51.

The risk ratio of major events in the two groups of participants during the follow-up period

After a median follow-up of 6.
9 years (IQR 6.
5-7.
2), the primary endpoint of the intervention group (4456/13979 [31.
9%]; 5.
45/100 person-years [95%CI 5.
52-5.
61]) was significantly less than the control group (4616/13996 [33.
0%]; every 5.
68/100 person-years [5.
52-5.
85]; hazard ratio 0.
96 [95%CI 0.
92-1.
00]; P=0.
045)
.

After a median follow-up of 6.
9 years (IQR 6.
5-7.
2), the primary endpoint of the intervention group (4456/13979 [31.
9%]; 5.
45/100 person-years [95%CI 5.
52-5.
61]) was significantly less than the control group (4616/13996 [33.
0%]; every 5.
68/100 person-years [5.
52-5.
85]; hazard ratio 0.
96 [95%CI 0.
92-1.
00]; P=0.
045)
.

After a median follow-up of 6.

It can be seen that compared with standard care, screening for atrial fibrillation shows a small net benefit, indicating that screening is safe and beneficial in the elderly

references:

Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial.

Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial.

Leave a message here